Blood Proteins

Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins.
DrugDrug NameDrug Description
DB00002CetuximabAn endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
DB00009AlteplaseA recombinant form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
DB00013UrokinaseA low molecular weight form of human urokinase used to treat pulmonary embolism and myocardial infarction as well as to clear IV lines.
DB00015ReteplaseA purified form of human tissue plasminogen activator used in the emergency treatment of myocardial infarction, ischemic stroke, and pulmonary emboli.
DB00025Antihemophilic factor, human recombinantA form of recombinant coagulation Factor VIII used to treat hemophilia A, von Willebrand disease, and Factor XIII deficiency.
DB00028Human immunoglobulin GA purified form of human immunoglobulin G and other proteins used to treat immunodeficiency and a wide variety of autoimmune disorders.
DB00029AnistreplaseA form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
DB00031TenecteplaseA modified form of recombinant human tissue plasminogen activator used in the emergency treatment of myocardial infarction and pulmonary emboli.
DB00036Coagulation factor VIIa Recombinant HumanA form of recombinant human coagulation Factor VII used to treat hemophilia A and B.
DB00043OmalizumabA monoclonal anti-immunoglobulin E antibody used in the treatment of severe asthma and chronic idiopathic urticaria.
DB00051AdalimumabA monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
DB00054AbciximabA monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.
DB00055Drotrecogin alfaA form of recombinant activated human protein C used to reduce mortality in patients with severe sepsis by inhibiting coagulation Factors V and VIII.
DB00056Gemtuzumab ozogamicinA monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia.
DB00057Indium In-111 satumomab pendetideFor diagnosis of extrahepatic malignant cancers
DB00058Alpha-1-proteinase inhibitorA purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency.
DB00062Albumin humanA purified form of human serum albumin used to replace lost albumin in patients with hypoalbuminemia, to treat hypovolemia and ascites, and as a part of some diagnostic imaging kits.
DB00065InfliximabA monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
DB00072TrastuzumabA monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.
DB00073RituximabA monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
DB00074BasiliximabA monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.
DB00075MuromonabA monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients.
DB00078Ibritumomab tiuxetanA monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
DB00081TositumomabA monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
DB00086StreptokinaseA purified fibrinolytic bacterial protein used to breakdown thrombosis in myocardial infarction, pulmonary embolism, and venous thromboembolism.
DB00087AlemtuzumabA monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
DB00089Capromab pendetideA monoclonal anti-prostate specific membrane antigen antibody used in imaging kits to target radioactive agents to malignant prostate tissue.
DB00095EfalizumabA monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis.
DB00098Antithymocyte immunoglobulin (rabbit)A purified form of rabbit anti-thymocyte antibodies used for immunosuppression in patients receiving kidney transplants.
DB00102BecaplerminA recombinant form of human platelet-derived growth factor used to treat ulcers due to diabetic neuropathy in the lower extremities when there is adequate blood supply to the area.
DB00108NatalizumabA monoclonal anti-integrin antibody which binds to the alpha 4 subunit of integrins to prevent migration of immune cells, and is used to treat Crohn's disease or multiple sclerosis.
DB00110PalivizumabA monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.
DB00111DaclizumabA monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.
DB00112BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in the treatment of many cancer types in combination with other antineoplastics.
DB00113Technetium Tc-99m arcitumomabFor imaging colorectal tumors
DB01257EculizumabA recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
DB01269PanitumumabA recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
DB01270RanibizumabA recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
DB01277MecaserminA recombinant insulin-like growth factor-1 used for the long-term treatment of growth failure in pediatric patients with primary IGF-1 deficiency or with growth hormone gene deletion due to the development of neutralizing antibodies to GH.
DB01281AbataceptA disease-modifying antirheumatic drug (DMARD) used for the management of moderate-to-severe active rheumatoid arthritis and active polyarticular juvenile idiopathic arthritis as monotherapy or in combination with other DMARDs.
DB01373CalciumA mineral found in over-the-counter supplements or prescription formulations used for the treatment of specific medical conditions related to calcium deficiency.
DB02261Platelet Activating FactorNot Available
DB04901GaliximabInvestigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.
DB04925DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
DB04945HemoglobinAn iron-containing protein found in all red blood cells (RBCs) for proper binding of oxygen and transport throughout the body, included in blood transfusions in severe hemorrhage.
DB04949PexelizumabFor the treatment of inflammation during cardiac surgery.
DB04956AfelimomabInvestigated for use/treatment in sepsis and septicemia.
DB04958EpratuzumabInvestigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
DB04962BectumomabInvestigated for use/treatment in lymphoma (non-hodgkin's).
DB04964OregovomabInvestigated for use/treatment in ovarian cancer.
DB04988IGN311Intended for the treatment of various forms of cancer.
DB05006AdecatumumabInvestigated for use/treatment in breast cancer and prostate cancer.
DB05097LabetuzumabLabetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"
DB05101MatuzumabInvestigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.
DB05111FontolizumabInvestigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
DB05136BavituximabInvestigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors.
DB05139CR002Investigated for use/treatment in nephropathy.
DB05209RozrolimupabInvestigated for use/treatment in thrombocytopenia.
DB05276Hepatitis B Immune GlobulinAn injection of immunoglobulin G (IgG) antibodies to prevent the development of chronic Hepatitis B infection.
DB05336ObiltoxaximabA monoclonal antibody used for prophylaxis or treatment of inhalational anthrax.
DB05405XTL-001Investigated for use/treatment in hepatitis (viral, B).
DB05437NAV 1800Investigated for use/treatment in colorectal cancer and solid tumors.
DB05459BriakinumabInvestigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis.
DB05496OtelixizumabInvestigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.
DB05545AMG 108Investigated for use/treatment in osteoarthritis and rheumatoid arthritis.
DB05550IratumumabInvestigated for use/treatment in lymphoma (unspecified).
DB05555EnokizumabInvestigated for use/treatment in asthma.
DB05578RamucirumabAn antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.
DB05595FarletuzumabInvestigated for use/treatment in ovarian cancer.
DB05656VeltuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's).
DB05679UstekinumabA targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.
DB05773Trastuzumab emtansineAn antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.
DB05793PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
DB05797TNX-901Investigated for use/treatment in allergic reaction.
DB05889Inotuzumab ozogamicinAn antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
DB05892RI 624Investigated for use/treatment in pain (acute or chronic).
DB05915MYO-029Investigated for use/treatment in muscular dystrophy.
DB05931PegdinetanibInvestigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
DB05941LeronlimabInvestigated for use/treatment in HIV infection.
DB05996Glembatumumab vedotinInvestigated for use/treatment in melanoma.
DB06043OlaratumabA platelet-derived growth factor receptor alpha blocking antibody used with doxorubicin to treat patients with certain types of soft tissue sarcoma (STS).
DB06049IPH 2101Investigated for use/treatment in leukemia (myeloid) and multiple myeloma.
DB06050TB-402Investigated for use/treatment in atrial fibrillation and thrombosis.
DB06081CaplacizumabA von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP).
DB06101IMC-1C11Investigated for use/treatment in cancer/tumors (unspecified).
DB06116EldelumabInvestigated for use/treatment in ulcerative colitis.
DB06162LumiliximabInvestigated for use/treatment in asthma and leukemia (lymphoid).
DB06168CanakinumabAn interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA).
DB06186IpilimumabA human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
DB06192NimotuzumabInvestigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.
DB06241ClenoliximabInvestigated for use/treatment in rheumatoid arthritis.
DB06245LanoteplaseInvestigated for use/treatment in myocardial infarction.
DB06273TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
DB06304BIIB015Investigated for use/treatment in solid tumors.
DB06310MotavizumabInvestigated for use/treatment in viral infection and pediatric indications.
DB06317ElotuzumabAn antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents.
DB06318AVE9633Investigated for use/treatment in leukemia (myeloid).
DB06322CarotuximabInvestigated for use/treatment in solid tumors.
DB06324XmAb 2513Investigated for use/treatment in lymphoma (unspecified) and lymphoma (non-hodgkin's).
DB06342Coltuximab ravtansineInvestigated for use/treatment in lymphoma (non-hodgkin's).
DB06343TeprotumumabInvestigated for use/treatment in solid tumors.
DB06360LucatumumabInvestigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).
DB06366PertuzumabAn antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents.
DB06371SiplizumabInvestigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
DB06404Human C1-esterase inhibitorA C1 inhibitor used to prevent angioedema attacks associated with hereditary angioedema.
DB06467ApolizumabInvestigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors.
DB06474SibrotuzumabInvestigated for use/treatment in cancer/tumors (unspecified), colorectal cancer, and lung cancer.
DB06550BivatuzumabInvestigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer.
DB06557LerdelimumabInvestigated for use/treatment in glaucoma and cataracts.
DB06599LexatumumabInvestigated for use/treatment in cancer/tumors (unspecified).
DB06602ReslizumabAn IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults.
DB06606TeplizumabInvestigated for use/treatment in diabetes mellitus type 1.
DB06607CatumaxomabFor use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label].
DB06612MepolizumabAn IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults.
DB06643DenosumabA RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures.
DB06647VolociximabInvestigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
DB06650OfatumumabA CD20 inhibitor used for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
DB06674GolimumabA TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
DB06679AmediplaseInvestigated for use/treatment in myocardial infarction and thrombosis.
DB06681BelataceptA selective T-cell costimulation blocker used in the prophylaxis of organ rejection in adult patients receiving a kidney transplant.
DB08870Brentuximab vedotinA CD30-directed antibody-drug conjugate used to treat various types of lymphoma.
DB08879BelimumabA B-lymphocyte stimulator (BLyS)-specific inhibitor that indirectly inhibits B cell survival, and is used to treat patients with autoantibody positive, active systemic lupus erythematosus.
DB08902RaxibacumabA monoclonal antibody used in conjunction with an antibacterial regimen to treat patients with inhalational anthrax caused by Bacillus anthracis and for prophylaxis of inhalational anthrax when appropriate.
DB08935ObinutuzumabAn antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.
DB09029SecukinumabAn immunomodulating agent and interleukin antagonist used to manage moderate to severe plaque psoriasis and active psoriatic arthritis or ankylosing spondylitis.
DB09033VedolizumabAn integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults with inadequate clinical response to immunomodulators.
DB09035NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
DB09036SiltuximabAn interleukin antagonist used to treat multicentric Castleman's disease (MCD) in patients who are HIV and HHV-8 negative.
DB09037PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
DB09045DulaglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
DB09052BlinatumomabAn antineoplastic antibody used to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
DB09077DinutuximabAn immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
DB09105Asfotase alfaAn enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP).
DB09109Turoctocog alfaAn antihemorrhagic agent used for the treatment and prophylaxis of bleeding in patients of all ages with haemophilia A (congenital factor VIII deficiency).
DB09222Fibrinogen humanA hemostatic agent used for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
DB09264IdarucizumabAn antibody that binds dabigatran for the reversal of anticoagulant effects of dabigatran.
DB09302AlirocumabA PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C).
DB09303EvolocumabA PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures.
DB09331DaratumumabA CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma.
DB09559NecitumumabA monoclonal antibody used to treat metastatic squamous non-small cell lung cancer.
DB11300ThrombinA coagulation factor used to stop bleeding during surgery.
DB11311ProthrombinA coagulation factor used for emergency reversal of vitamin K antagonist therapy.
DB11312Protein CA medication used to treat protein C deficiency leading to purpura fulminans or coumarin-induced skin necrosis.
DB11330Factor IX Complex (Human)A Factor IX complex used to prevent and treat bleeding episodes in hemophilia B or vitamin K antagonist therapy.
DB11569IxekizumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
DB11595AtezolizumabA monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
DB11598Antithrombin III humanAn alpha-2-glycoprotein used to prevent thromboembolisms in patients with hereditary antithrombin III deficiency.
DB11621Human Varicella-Zoster Immune GlobulinA solution of antibodies used for post exposure prophylaxis of varicella infections in high risk populations, as well as to reduce the severity of infections.
DB11646ConatumumabConatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.
DB11657TabalumabTabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.
DB11668Rusalatide acetateChrysalin has been used in trials studying the treatment of Radius Fracture.
DB11680FiclatuzumabFiclatuzumab has been used in trials studying the treatment of Acute Myeloid Leukemia, Non-small Cell Lung Cancer, Mullerian Mixed Tumor of Ovary, Relapsed Acute Myeloid Leukemia, and Refractory Acute Myeloid...
DB11685FigitumumabFigitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.
DB11714DurvalumabA monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.
DB11715BapineuzumabBapineuzumab has been investigated for the treatment of Alzheimer's Disease.
DB11746OnartuzumabOnartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
DB11756SolanezumabSolanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
DB11767SarilumabA monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs.
DB11771TremelimumabTremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part...
DB11776BrodalumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
DB11803SirukumabSirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
DB11826LampalizumabLampalizumab has been used in trials studying the treatment of Geographic Atrophy.
DB11834GuselkumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
DB11840DalotuzumabDalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.
DB11849EmibetuzumabEmibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
DB11856LigelizumabLigelizumab has been used in trials studying the basic science and treatment of Asthma, Allergy, Peanut Allergy, Allergic Asthma, and Atopic Dermatitis, among others.
DB11857SeribantumabSeribantumab has been used in trials studying the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers, among others.
DB11862LandogrozumabLandogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer.
DB11866RomosozumabA monoclonal antibody used to treat osteoporosis in postmenopausal women at high risk of fracture, patients who are intolerant of other treatments, or patients who have failed other treatments.
DB11945AvelumabA monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
DB11959CrenezumabCrenezumab has been used in trials studying the treatment of Alzheimer's Disease.
DB11972RilotumumabRilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.
DB11976AnifrolumabAnifrolumab has been investigated for the treatment of Scleroderma.
DB11988OcrelizumabA CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis.
DB12034GantenerumabGantenerumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
DB12053VisilizumabVisilizumab has been investigated for the treatment of Ulcerative Colitis.
DB12089Lorvotuzumab mertansineLorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
DB12090PatritumabPatritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
DB12102FulranumabFulranumab has been used in trials studying the treatment of Pain, Cystitis, Neuralgia, Joint Pain, and Arthralgia, among others.
DB12104TarextumabTarextumab has been used in trials studying the treatment of Solid Tumors, Stage IV Pancreatic Cancer, and Stage IV Small Cell Lung Cancer.
DB12119GevokizumabGevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine...
DB12142DuligotuzumabDuligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.
DB12159DupilumabA monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps accompanied by chronic rhinosinusitis in adolescents and adults.
DB12169TralokinumabTralokinumab is under investigation for the treatment of Alopecia Areata. Tralokinumab has been investigated for the treatment of Asthma.
DB12189EtrolizumabEtrolizumab has been used in trials studying the treatment of Crohn Disease and Ulcerative Colitis.
DB12205GanitumabGanitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.
DB12213EtaracizumabEtaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
DB12240Polatuzumab vedotinThis medication is indicated to treat adults with relapsed or refractory diffuse large B-cell lymphoma in combination with bendamustine and rituximab that has returned of progressed after 2 or more...
DB12246InclacumabInclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.
DB12250CixutumumabCixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate. Cixutumumab is a highly specific recombinant...
DB12261AscrinvacumabAscrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.
DB12274AducanumabAducanumab has been used in trials studying the treatment of Alzheimer's Disease.
DB12335TanezumabTanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.
DB12363DusigitumabDusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer.
DB12396FresolimumabFresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis.
DB12409Vatreptacog alfaVatreptacog Alfa (Activated) has been used in trials studying the treatment of Haemophilia B, Haemophilia A, Congenital Bleeding Disorder, Haemophilia A With Inhibitors, and Haemophilia B With Inhibitors.
DB12456BococizumabBococizumab has been used in trials studying the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia.
DB12489Mirvetuximab SoravtansineMirvetuximab Soravtansine has been used in trials studying the treatment of Ovarian cancer, Endometrial Cancer, Fallopian tube cancer, Epithelial Ovarian Cancer, and Primary Peritoneal Cancer, among others.
DB12530InebilizumabInebilizumab has been used in trials studying the treatment of Blood Cancer, B-cell Malignancies, Advanced B Cell Malignancies, Chronic Lymphocytic Leukemia (CLL), and Diffuse Large B-Cell Lymphoma (DLBCL).
DB12534MavrilimumabMavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.
DB12560BlosozumabBlosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal.
DB12584BimagrumabBimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others.
DB12589DacetuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.
DB12609TovetumabTovetumab has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Advanced Solid Malignancies.
DB12698IbalizumabA CD4-specific antibody used to treat HIV infections.
DB12699BalugrastimBalugrastim has been used in trials studying the treatment of Solid Tumors.
DB12701IntetumumabIntetumumab has been used in trials studying the treatment of Melanoma.
DB12718CarlumabCarlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.
DB12726MonteplaseMonteplase has been used in trials studying the treatment of Pulmonary Embolism.
DB12732FirategrastFirategrast has been used in trials studying the treatment of Multiple Sclerosis.
DB12734DemcizumabDemcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
DB12775AbituzumabAbituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic.
DB12807Naptumomab EstafenatoxNaptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
DB12815CrotedumabCrotedumab has been used in trials studying the treatment of Diabetes Mellitus, Type 2.
DB12820ConcizumabConcizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder.
DB12826DepatuxizumabDepatuxizumab has been used in trials studying the treatment and diagnostic of Adenocarcinoma and Advanced Solid Tumors.
DB12844RontalizumabRontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus.
DB12845AmatuximabAmatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
DB12849ClazakizumabClazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
DB12891OzanezumabOzanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting.
DB12893Sacituzumab govitecanSacituzumab govitecan has been used in trials studying the treatment of Breast Cancer, Cervical Cancer, Renal Cell Cancer, Colorectal Cancer, and Esophageal Cancer, among others.
DB12909Factor XIII (human)A purified form of Factor XIII that is used to prevent and treat surgical bleeding in patients with a Factor XIII deficiency.
DB12943MilatuzumabMilatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
DB12976RobatumumabRobatumumab has been used in trials studying the treatment of Osteosarcoma, Sarcoma, Ewing's, and Peripheral Neuroectodermal Tumor.
DB13045RacotumomabRacotumomab has been used in trials studying the treatment of Glioma, Wilm's Tumor, Neuroblastoma, Retinoblastoma, and Ewing's Sarcoma.
DB13127OlokizumabOlokizumab has been used in trials studying the treatment of Crohn's Disease.
DB13133Von Willebrand Factor HumanA complex of von Willebrand Factor and Factor VIII used to treat bleeding episodes in von Willebrand disease.
DB13148Coagulation factor X humanA coagulation factor used to treat Factor X deficiency to control bleeding.
DB13149Protein S humanA medication used for emergency reversal of coagulation factor deficiency in vitamin K antagonist therapy.
DB13150Coagulation factor VII humanA coagulation factor used to treat bleeding disorders such as hemophilia and Glanzmann's thrombasthenia.
DB13192Antihemophilic factor humanA Factor VIII replacement therapy used to treat hemophilia A.
DB13197KallidinogenaseNot Annotated
DB13201Trenonacog alfaHuman coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component), produced in CHO cells.
DB13375EdrecolomabNot Annotated
DB13535NebacumabNot Annotated
DB13646SaruplaseNot Annotated
DB13864Hemoglobin crosfumarilHemoglobin in which the alpha-subunit are cross-linked intramolecularly.
DB13886Human cytomegalovirus immune globulinA solution of immune globulin G against cytomegalovirus used to prevent transmission of cytomegalovirus after organ transplants.
DB13923EmicizumabAn antibody against Factor IXa and Factor X used to treat hemophilia A.
DB13933Nonacog beta pegolA recombinant coagulation Factor IX derivative used to treat hemophilia B.
DB13968Plasma protein fraction (human)A plasma protein solution used to treat coagulation factor deficiencies, reverse anticoagulant effects, and shock from a loss of plasma fluids, and is also used in plasma exchange procedures.
DB13976SulesomabMarket product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
DB13979BesilesomabA monoclonal antibody bound to technetium-99 used to find infection and inflammation in patients with suspected osteomyelitis.
DB13999Moroctocog alfaA recombinant Factor VIII used to treat hemophilia A to control bleeding.
DB14004TildrakizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
DB14039ErenumabA calcitonin-gene related peptide antagonist used to prevent migraines.
DB14041FremanezumabA calcitonin-gene related peptide antagonist used to prevent migraines.
DB14211FanolesomabAn anti-SSEA-1 monoclonal antibody used for imaging of the appendix and to diagnose appendicitis.
DB14472Insulin-like growth factor IIThe insulin-like growth factor II is a well-characterized neutral peptide believed to be secreted by the liver and to circulate in the blood. This factor presents effects related to growth...
DB14473Beroctocog alfaNot Annotated
DB14562Andexanet alfaA recombinant Factor Xa used to reverse anticoagulation caused by rivaroxaban and apixaban.
DB12498MogamulizumabA monoclonal antibody used to treat relapsed or refractory mycosis fungoides or Sézary syndrome after attempting one other therapy.
DB14597LanadelumabA plasma kallikrein inhibitor used to treat attacks of hereditary angioedema.
DB09329Antihemophilic Factor (Recombinant), PEGylatedFor the management of hemophilia A (congenital factor VIII deficiency) [FDA label], . This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older)...
DB11914LebrikizumabLebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
DB12023BenralizumabA monoclonal antibody used to treat eosinophilic asthma.
DB12202ZalutumumabZalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell...
DB12520PlozalizumabPlozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including...
DB12773SifalimumabSifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders,...
DB14738Turoctocog alfa pegolTuroctocog alfa pegol (N8-GP) is indicated for use in adults and children of all ages with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis in reducing the frequency of...
DB05304GirentuximabInvestigated for use/treatment in gall bladder cancer and renal cell carcinoma.
DB14762RisankizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
DB14809Anetumab ravtansineAnetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).
DB14811IsatuximabIsatuximab is under investigation in clinical trial NCT02514668 (A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma).
DB14824IcrucumabIcrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).
DB14852PRM-151PRM-151 is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis).
DB14877LintuzumabLintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
DB14891VobarilizumabVobarilizumab is under investigation in clinical trial NCT02101073 (ALX-0061 Phase I Bioavailability Study in Healthy Volunteers).
DB14905EmactuzumabEmactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).
DB14907Bevacizumab zirconium Zr-89Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).
DB14908RefanezumabRefanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).
DB14952PamrevlumabPamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).
DB14988DalanterceptDalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).
DB14997PateclizumabPateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in...
DB15022ApomabApomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and...
DB15045IpafriceptIpafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).
DB15076AbrilumabAbrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).
DB15101TigatuzumabTigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)).
DB15113UtomilumabUtomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).
DB15118ZolbetuximabZolbetuximab is under investigation in clinical trial NCT01630083 (Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer).
DB15135PonezumabPonezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
DB15150FibronectinFibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).
DB15160AsunerceptAsunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
DB15172SuvratoxumabSuvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
DB15225MitazalimabMitazalimab is under investigation in clinical trial NCT02379741 (ADC-1013 First-in-Human Study).
DB15253BleselumabBleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant...
DB15272EdratideEdratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus).
DB15336Valanafusp alfaValanafusp alfa is under investigation in clinical trial NCT03071341 (Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I).
DB15363IstiratumabIstiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).
DB15383PidilizumabPidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma).
DB15397GMA-161GMA-161 is under investigation in clinical trial NCT00244257 (Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)).
DB15409Ladiratuzumab vedotinLadiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).
DB15415TomaralimabTomaralimab is under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function).
DB15428VesencumabVesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors).
DB15432Pinatuzumab vedotinPinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With...
DB15441Lulizumab pegolLulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).
DB15443Lorukafusp alfaLorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).
DB15453Naratuximab emtansineNaratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia).
DB00092AlefaceptA recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
DB05916CT-011Investigated for use/treatment in cancer/tumors (unspecified).
DB06305SonepcizumabInvestigated for use/treatment in solid tumors.
DB11572Thrombin alfaA platelet activating factor used to treat minor bleeding.
DB11580RavulizumabA monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria.
DB11608Eftrenonacog alfaA recombinant Factor IX used to treat and prevent bleeding in hemophilia B.
DB11731Depatuxizumab mafodotinNo approved indication.
DB11850UblituximabUblituximab has been used in trials studying the treatment of B-cell Lymphoma, Neuromyelitis Optica, Mantle Cell Lymphoma, Non-Hodgkins Lymphoma, and Marginal Zone Lymphoma, among others.
DB11884Vadastuximab TalirineVadastuximab Talirine has been used in trials studying the treatment of Acute myeloid leukemia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, and Acute Promyelocytic Leukemia.
DB11930VarlilumabVarlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.
DB12077UrelumabUrelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody...
DB12152SimtuzumabSimtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis.
DB12157FasinumabFasinumab has been used in trials studying the basic science and treatment of Sciatica, Back Pain, Low Back Pain, Osteoarthritis, Hip, and Abdominal Pain Upper, among others.
DB12296GS-5745GS-5745 has been used in trials studying the treatment of Tumors, Breast Cancer, Crohn's Disease, Colorectal Cancer, and Pancreatic Cancer, among others.
DB12317VanucizumabVanucizumab has been used in trials studying the treatment of ColoRectal Cancer and Advanced/Metastatic Solid Tumors.
DB12331Labetuzumab govitecanLabetuzumab govitecan has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, and Metastatic Colorectal Cancer.
DB12342EnsituximabEnsituximab has been used in trials studying the treatment of Pancreatic Cancer, Adult, Metastatic Colorectal Cancer, and Metastatic Pancreatic Cancer.
DB12344FezakinumabFezakinumab has been used in trials studying the treatment of Atopic Dermatitis and Rheumatoid Arthritis.
DB12413Indusatumab vedotinIndusatumab vedotin has been used in trials studying the treatment of Pancreatic Adenocarcinoma, Adenocarcinoma of the Stomach, Recurrent Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, and Advanced Gastrointestinal Carcinoma, among others.
DB12683LumretuzumabLumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
DB12797EcromeximabEcromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma.
DB12917BimekizumabBimekizumab has been used in trials studying the treatment of Psoriatic arthritis, Ankylosing Spondylitis, Chronic Plaque Psoriasis, and Mild to Moderate Psoriasis.
DB12950AlbusomatropinAlbusomatropin has been used in trials studying the treatment of Growth Hormone-Deficiency and Growth Hormone Deficiency.
DB13017Rovalpituzumab TesirineRovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
DB13037NamilumabNamilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
DB13073TregalizumabTregalizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
DB13140BezlotoxumabA monoclonal antibody used to reduce the recurrence of Clostridium difficile infections.
DB13151Anti-inhibitor coagulant complexA medication used to control bleeding episodes and prevent bleeding episodes in hemophilia A and B.
DB13884Albutrepenonacog alfaA recombinant Factor IX fused to recombinant human albumin used to treat hemophilia B.
DB14012BurosumabA fibroblast growth factor 23 blocking antibody used to treat X-linked hypophosphatemia.
DB14040EptinezumabUse of eptinezumab is intended for migraine prevention [A33105, A33106, A33108].
DB14042GalcanezumabA calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches.
DB14580BAN-2401BAN-2401 is an experimental drug that is currently in clinical trials for the treament of Alzheimer's disease.
DB14707CemiplimabA programmed death receptor-1 blocking antibody used to treat metastatic cutaneous squamous cell carcinoma.
DB14776CamrelizumabCamrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
DB14778SetrusumabSetrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density).
DB14784GancotamabGancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
DB14843CodrituzumabCodrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma).
DB14864BrolucizumabAn anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.
DB14871XentuzumabXentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)).
DB14897ParsatuzumabParsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous...
DB14919RozanolixizumabRozanolixizumab is under investigation in clinical trial NCT03861481 (A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy).
DB14959OpicinumabOpicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants).
DB14962Trastuzumab deruxtecanTrastuzumab deruxtecan is under investigation in clinical trial NCT02564900 (Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors).
DB14967MargetuximabMargetuximab is under investigation in clinical trial NCT03133988 (Margetuximab Expanded Access Program).
DB15014GremubamabGremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).
DB15044TafasitamabTafasitamab is under investigation in clinical trial NCT02005289 (Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated...
DB15089FrovocimabFrovocimab is under investigation in clinical trial NCT01671085 (A Study of LY3015014 in Healthy Participants With High Cholesterol).
DB15090TezepelumabTezepelumab is under investigation in clinical trial NCT03406078 (Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma).
DB15104Telisotuzumab vedotinTelisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
DB15128RemtolumabRemtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study).
DB15252NemolizumabNemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).
DB15277GedivumabGedivumab is under investigation in clinical trial NCT01877785 (A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers).
DB15349Sofituzumab vedotinSofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).
DB15354EvinacumabEvinacumab is under investigation in clinical trial NCT03146416 (Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers).
DB15559ZenocutuzumabZenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).
DrugDrug NameTargetType
DB00002CetuximabEpidermal growth factor receptortarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00002CetuximabComplement C1r subcomponenttarget
DB00002CetuximabComplement C1q subcomponent subunit Atarget
DB00002CetuximabComplement C1q subcomponent subunit Btarget
DB00002CetuximabComplement C1q subcomponent subunit Ctarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00002CetuximabComplement C1s subcomponenttarget
DB00002CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00009AlteplaseUrokinase plasminogen activator surface receptortarget
DB00009AlteplaseFibrinogen alpha chaintarget
DB00009AlteplasePlasminogentarget
DB00009AlteplasePlasminogen activator inhibitor 1target
DB00013UrokinaseUrokinase plasminogen activator surface receptortarget
DB00013UrokinasePlasminogentarget
DB00013UrokinaseUrokinase-type plasminogen activatortarget
DB00013UrokinaseTissue-type plasminogen activatortarget
DB00013UrokinasePlasminogen activator inhibitor 2target
DB00013UrokinasePlasminogen activator inhibitor 1target
DB00013UrokinasePlasma serine protease inhibitortarget
DB00013UrokinaseNidogen-1target
DB00013UrokinaseLow-density lipoprotein receptor-related protein 2target
DB00013UrokinaseSuppressor of tumorigenicity 14 proteintarget
DB00015ReteplaseUrokinase plasminogen activator surface receptortarget
DB00015ReteplaseFibrinogen alpha chaintarget
DB00015ReteplasePlasminogentarget
DB00015ReteplasePlasminogen activator inhibitor 1target
DB00025Antihemophilic factor, human recombinantCoagulation factor Xtarget
DB00025Antihemophilic factor, human recombinantPhytanoyl-CoA dioxygenase, peroxisomaltarget
DB00025Antihemophilic factor, human recombinantCoagulation factor IXtarget
DB00025Antihemophilic factor, human recombinantAsialoglycoprotein receptor 2target
DB00025Antihemophilic factor, human recombinant78 kDa glucose-regulated proteintarget
DB00025Antihemophilic factor, human recombinantCalreticulintarget
DB00025Antihemophilic factor, human recombinantCalnexintarget
DB00025Antihemophilic factor, human recombinantProtein ERGIC-53target
DB00025Antihemophilic factor, human recombinantProlow-density lipoprotein receptor-related protein 1target
DB00025Antihemophilic factor, human recombinantMultiple coagulation factor deficiency protein 2target
DB00025Antihemophilic factor, human recombinantvon Willebrand factortarget
DB00025Antihemophilic factor, human recombinantProthrombinenzyme
DB00025Antihemophilic factor, human recombinantVitamin K-dependent protein Cenzyme
DB00028Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00028Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00028Human immunoglobulin GHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00028Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00028Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00028Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00028Human immunoglobulin GHigh affinity immunoglobulin gamma Fc receptor IBtarget
DB00028Human immunoglobulin GComplement C3target
DB00028Human immunoglobulin GComplement C4-Atarget
DB00028Human immunoglobulin GComplement C4-Btarget
DB00028Human immunoglobulin GComplement C5target
DB00029AnistreplaseUrokinase plasminogen activator surface receptortarget
DB00029AnistreplaseFibrinogen alpha chaintarget
DB00029AnistreplasePlasminogentarget
DB00029AnistreplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseUrokinase plasminogen activator surface receptortarget
DB00031TenecteplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseFibrinogen alpha chaintarget
DB00031TenecteplasePlasminogen activator inhibitor 2target
DB00031TenecteplaseTetranectintarget
DB00031TenecteplaseKeratin, type II cytoskeletal 8target
DB00031TenecteplaseAnnexin A2target
DB00031TenecteplaseCalreticulintarget
DB00031TenecteplaseCalnexintarget
DB00031TenecteplaseProlow-density lipoprotein receptor-related protein 1target
DB00031TenecteplasePlasminogentarget
DB00036Coagulation factor VIIa Recombinant HumanCoagulation factor Xtarget
DB00036Coagulation factor VIIa Recombinant HumanTissue factortarget
DB00036Coagulation factor VIIa Recombinant HumanSerine protease hepsintarget
DB00036Coagulation factor VIIa Recombinant HumanTissue factor pathway inhibitortarget
DB00036Coagulation factor VIIa Recombinant HumanVitamin K-dependent gamma-carboxylasetarget
DB00036Coagulation factor VIIa Recombinant HumanCoagulation factor VIItarget
DB00043OmalizumabHigh affinity immunoglobulin epsilon receptor subunit alphatarget
DB00043OmalizumabHigh affinity immunoglobulin epsilon receptor subunit betatarget
DB00051AdalimumabTumor necrosis factortarget
DB00054AbciximabIntegrin beta-3target
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00054AbciximabComplement C1r subcomponenttarget
DB00054AbciximabComplement C1q subcomponent subunit Atarget
DB00054AbciximabComplement C1q subcomponent subunit Btarget
DB00054AbciximabComplement C1q subcomponent subunit Ctarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00054AbciximabComplement C1s subcomponenttarget
DB00054AbciximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00054AbciximabIntegrin alpha-IIbtarget
DB00054AbciximabVitronectintarget
DB00055Drotrecogin alfaCoagulation factor VIIItarget
DB00055Drotrecogin alfaCoagulation factor Vtarget
DB00055Drotrecogin alfaPlasminogen activator inhibitor 1target
DB00055Drotrecogin alfaThrombomodulintarget
DB00055Drotrecogin alfaVitamin K-dependent protein Starget
DB00055Drotrecogin alfaCeruloplasmintarget
DB00055Drotrecogin alfaProthrombintarget
DB00055Drotrecogin alfaPlatelet factor 4target
DB00055Drotrecogin alfaPlasma serine protease inhibitortarget
DB00055Drotrecogin alfaSerpin B6target
DB00055Drotrecogin alfaVitamin K-dependent gamma-carboxylasetarget
DB00055Drotrecogin alfaEndothelial protein C receptortarget
DB00056Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00056Gemtuzumab ozogamicinComplement C1r subcomponenttarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Atarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Btarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Ctarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00056Gemtuzumab ozogamicinComplement C1s subcomponenttarget
DB00056Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00057Indium In-111 satumomab pendetideTumor-associated glycoprotein 72 (TAG-72)target
DB00058Alpha-1-proteinase inhibitorNeutrophil elastasetarget
DB00062Albumin humanNitric oxidetarget
DB00065InfliximabTumor necrosis factortarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00072TrastuzumabComplement C1r subcomponenttarget
DB00072TrastuzumabComplement C1q subcomponent subunit Atarget
DB00072TrastuzumabComplement C1q subcomponent subunit Btarget
DB00072TrastuzumabComplement C1q subcomponent subunit Ctarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00072TrastuzumabComplement C1s subcomponenttarget
DB00072TrastuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00072TrastuzumabReceptor tyrosine-protein kinase erbB-2target
DB00072TrastuzumabEpidermal growth factor receptortarget
DB00073RituximabB-lymphocyte antigen CD20target
DB00074BasiliximabInterleukin-2 receptor subunit alphatarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00074BasiliximabComplement C1r subcomponenttarget
DB00074BasiliximabComplement C1q subcomponent subunit Atarget
DB00074BasiliximabComplement C1q subcomponent subunit Btarget
DB00074BasiliximabComplement C1q subcomponent subunit Ctarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00074BasiliximabComplement C1s subcomponenttarget
DB00074BasiliximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00074BasiliximabInterleukin-2 receptor subunit betatarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00075MuromonabT-cell surface glycoprotein CD3 epsilon chaintarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00075MuromonabComplement C1r subcomponenttarget
DB00075MuromonabComplement C1q subcomponent subunit Atarget
DB00075MuromonabComplement C1q subcomponent subunit Btarget
DB00075MuromonabComplement C1q subcomponent subunit Ctarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00075MuromonabComplement C1s subcomponenttarget
DB00075MuromonabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00075MuromonabT-cell surface glycoprotein CD3 delta chaintarget
DB00075MuromonabT-cell surface glycoprotein CD3 gamma chaintarget
DB00075MuromonabT-cell surface glycoprotein CD3 zeta chaintarget
DB00078Ibritumomab tiuxetanB-lymphocyte antigen CD20target
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00078Ibritumomab tiuxetanComplement C1r subcomponenttarget
DB00078Ibritumomab tiuxetanComplement C1q subcomponent subunit Atarget
DB00078Ibritumomab tiuxetanComplement C1q subcomponent subunit Btarget
DB00078Ibritumomab tiuxetanComplement C1q subcomponent subunit Ctarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00078Ibritumomab tiuxetanComplement C1s subcomponenttarget
DB00078Ibritumomab tiuxetanHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00081TositumomabB-lymphocyte antigen CD20target
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00081TositumomabComplement C1r subcomponenttarget
DB00081TositumomabComplement C1q subcomponent subunit Atarget
DB00081TositumomabComplement C1q subcomponent subunit Btarget
DB00081TositumomabComplement C1q subcomponent subunit Ctarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00081TositumomabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00086StreptokinasePlasminogentarget
DB00086StreptokinaseProteinase-activated receptor 1target
DB00086StreptokinaseCytosolic phospholipase A2enzyme
DB00087AlemtuzumabCAMPATH-1 antigentarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00087AlemtuzumabComplement C1r subcomponenttarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Atarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Btarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Ctarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00087AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00089Capromab pendetideGlutamate carboxypeptidase 2target
DB00095EfalizumabIntegrin alpha-Ltarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00095EfalizumabComplement C1r subcomponenttarget
DB00095EfalizumabComplement C1q subcomponent subunit Atarget
DB00095EfalizumabComplement C1q subcomponent subunit Btarget
DB00095EfalizumabComplement C1q subcomponent subunit Ctarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00095EfalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00098Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD1atarget
DB00098Antithymocyte immunoglobulin (rabbit)Major histocompatibility complex class I-related gene proteintarget
DB00098Antithymocyte immunoglobulin (rabbit)Integrin alpha-Ltarget
DB00098Antithymocyte immunoglobulin (rabbit)T-lymphocyte activation antigen CD86target
DB00098Antithymocyte immunoglobulin (rabbit)Low affinity immunoglobulin gamma Fc region receptor II-btarget
DB00098Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD4target
DB00098Antithymocyte immunoglobulin (rabbit)Integrin beta-1target
DB00098Antithymocyte immunoglobulin (rabbit)Integrin alpha-Vtarget
DB00098Antithymocyte immunoglobulin (rabbit)Integrin beta-3target
DB00102BecaplerminPlatelet-derived growth factor receptor betatarget
DB00102BecaplerminAlpha-2-macroglobulintarget
DB00102BecaplerminPlatelet-derived growth factor receptor alphatarget
DB00108NatalizumabIntegrin alpha-4target
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00108NatalizumabComplement C1r subcomponenttarget
DB00108NatalizumabComplement C1q subcomponent subunit Atarget
DB00108NatalizumabComplement C1q subcomponent subunit Btarget
DB00108NatalizumabComplement C1q subcomponent subunit Ctarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00108NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00108NatalizumabIntercellular adhesion molecule 1target
DB00110PalivizumabFusion glycoprotein F0target
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00110PalivizumabComplement C1r subcomponenttarget
DB00110PalivizumabComplement C1q subcomponent subunit Atarget
DB00110PalivizumabComplement C1q subcomponent subunit Btarget
DB00110PalivizumabComplement C1q subcomponent subunit Ctarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00110PalivizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00111DaclizumabInterleukin-2 receptor subunit alphatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00111DaclizumabComplement C1r subcomponenttarget
DB00111DaclizumabComplement C1q subcomponent subunit Atarget
DB00111DaclizumabComplement C1q subcomponent subunit Btarget
DB00111DaclizumabComplement C1q subcomponent subunit Ctarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00111DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00111DaclizumabInterleukin-2 receptor subunit betatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00112BevacizumabComplement C1r subcomponenttarget
DB00112BevacizumabComplement C1q subcomponent subunit Atarget
DB00112BevacizumabComplement C1q subcomponent subunit Btarget
DB00112BevacizumabComplement C1q subcomponent subunit Ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00112BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabVascular endothelial growth factor Atarget
DB00113Technetium Tc-99m arcitumomabCarcinoembryonic antigen-related cell adhesion molecule 1target
DB01257EculizumabComplement C5target
DB01269PanitumumabEpidermal growth factor receptortarget
DB01270RanibizumabVascular endothelial growth factor Atarget
DB01277MecaserminInsulin-like growth factor 1 receptortarget
DB01277MecaserminInsulin-like growth factor-binding protein 3target
DB01277MecaserminInsulin receptortarget
DB01277MecaserminCation-independent mannose-6-phosphate receptortarget
DB01277MecaserminInsulin-like growth factor-binding protein 3carrier
DB01277MecaserminInsulin-like growth factor-binding protein complex acid labile subunitcarrier
DB01277MecaserminInsulin-like growth factor-binding protein 1carrier
DB01277MecaserminInsulin-like growth factor-binding protein 2carrier
DB01277MecaserminInsulin-like growth factor-binding protein 4carrier
DB01277MecaserminInsulin-like growth factor-binding protein 5carrier
DB01277MecaserminInsulin-like growth factor-binding protein 6carrier
DB01281AbataceptT-lymphocyte activation antigen CD80target
DB01281AbataceptT-lymphocyte activation antigen CD86target
DB01373CalciumProtein S100-Btarget
DB01373CalciumCalpastatintarget
DB01373CalciumCartilage oligomeric matrix proteintarget
DB01373CalciumCalmodulintarget
DB01373CalciumSpectrin beta chain, non-erythrocytic 1target
DB01373CalciumVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB01373CalciumTroponin C, skeletal muscletarget
DB01373CalciumTroponin C, slow skeletal and cardiac musclestarget
DB01373CalciumCalcium-transporting ATPase type 2C member 1target
DB01373CalciumAmiloride-sensitive amine oxidase [copper-containing]target
DB01373CalciumProtein S100-A13target
DB01373CalciumAlkaline phosphatase, placental typetarget
DB01373CalciumProtein S100-A8target
DB01373CalciumProtein S100-A9target
DB01373CalciumProtein S100-A2target
DB01373CalciumCeruloplasmintarget
DB01373CalciumBone morphogenetic protein 4target
DB01373CalciumMatrix Gla proteintarget
DB01373CalciumProtocadherin-19target
DB01373CalciumProgrammed cell death protein 6target
DB02261Platelet Activating FactorGanglioside GM2 activatortarget
DB02261Platelet Activating FactorP-glycoprotein 1transporter
DB02261Platelet Activating FactorPlatelet-activating factor receptortarget
DB04901GaliximabT-lymphocyte activation antigen CD80target
DB04925DesmoteplasePlasminogentarget
DB04956AfelimomabTumor necrosis factortarget
DB04958EpratuzumabB-cell receptor CD22target
DB04964OregovomabMucin-16target
DB04988IGN311Epidermal growth factor receptortarget
DB04988IGN311Receptor tyrosine-protein kinase erbB-2target
DB05097LabetuzumabCarcinoembryonic antigen-related cell adhesion molecule 5target
DB05101MatuzumabEpidermal growth factor receptortarget
DB05111FontolizumabInterferon gammatarget
DB05139CR002Platelet-derived growth factor Dtarget
DB05209RozrolimupabRhesus blood group D antigentarget
DB05276Hepatitis B Immune GlobulinHBsAgtarget
DB05459BriakinumabInterleukin-12 subunit betatarget
DB05459BriakinumabInterleukin-23 subunit alphatarget
DB05578RamucirumabVascular endothelial growth factor receptor 2target
DB05595FarletuzumabFolate receptor alphatarget
DB05679UstekinumabInterleukin-12 subunit betatarget
DB05679UstekinumabInterleukin-23target
DB05773Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
DB05773Trastuzumab emtansineP-glycoprotein 1transporter
DB05773Trastuzumab emtansineCytochrome P450 3A4enzyme
DB05773Trastuzumab emtansineCytochrome P450 3A5enzyme
DB05793PRO-542Free fatty acid receptor 4target
DB05797TNX-901High affinity immunoglobulin epsilon receptor subunit alphatarget
DB05889Inotuzumab ozogamicinP-glycoprotein 1transporter
DB05889Inotuzumab ozogamicinB-cell receptor CD22target
DB05892RI 624Beta-nerve growth factortarget
DB05915MYO-029Growth/differentiation factor 8target
DB05931PegdinetanibVascular endothelial growth factor receptor 2target
DB05941LeronlimabC-C chemokine receptor type 5target
DB05996Glembatumumab vedotinTransmembrane glycoprotein NMBtarget
DB06043OlaratumabPlatelet-derived growth factor receptor alphatarget
DB06050TB-402Coagulation factor VIIItarget
DB06081Caplacizumabvon Willebrand factortarget
DB06101IMC-1C11Vascular endothelial growth factor receptor 1target
DB06101IMC-1C11Vascular endothelial growth factor receptor 2target
DB06101IMC-1C11Vascular endothelial growth factor receptor 3target
DB06116EldelumabC-X-C motif chemokine 10target
DB06162LumiliximabLow affinity immunoglobulin epsilon Fc receptortarget
DB06168CanakinumabInterleukin-1 betatarget
DB06186IpilimumabCytotoxic T-lymphocyte protein 4target
DB06241ClenoliximabT-cell surface glycoprotein CD4target
DB06245LanoteplaseUrokinase plasminogen activator surface receptortarget
DB06245LanoteplaseFibrinogen alpha chaintarget
DB06245LanoteplaseKallikrein-1target
DB06245LanoteplaseLaminin subunit alpha-5target
DB06245LanoteplaseCoagulation factor Xtarget
DB06245LanoteplaseFibronectintarget
DB06245LanoteplasePlasminogen activator inhibitor 2target
DB06245LanoteplaseTetranectintarget
DB06245LanoteplaseKeratin, type II cytoskeletal 8target
DB06245LanoteplaseAnnexin A2target
DB06245LanoteplaseLaminin subunit beta-1target
DB06245LanoteplaseLaminin subunit gamma-1target
DB06245LanoteplaseLaminin subunit alpha-1target
DB06245LanoteplaseCalreticulintarget
DB06245LanoteplaseCalnexintarget
DB06245LanoteplaseProlow-density lipoprotein receptor-related protein 1target
DB06245LanoteplaseLaminin subunit alpha-3target
DB06273TocilizumabInterleukin-6 receptor subunit alphatarget
DB06273TocilizumabCytochrome P450 3A4enzyme
DB06317ElotuzumabSLAM family member 7target
DB06318AVE9633Myeloid cell surface antigen CD33target
DB06318AVE9633Cytochrome P450 3A4enzyme
DB06322CarotuximabEndoglintarget
DB06324XmAb 2513Tumor necrosis factor receptor superfamily member 8target
DB06342Coltuximab ravtansineB-lymphocyte antigen CD19target
DB06342Coltuximab ravtansineCytochrome P450 3A4enzyme
DB06343TeprotumumabInsulin-like growth factor 1 receptortarget
DB06360LucatumumabTumor necrosis factor receptor superfamily member 5target
DB06366PertuzumabReceptor tyrosine-protein kinase erbB-2target
DB06371SiplizumabT-cell surface antigen CD2target
DB06404Human C1-esterase inhibitorComplement C1r subcomponenttarget
DB06404Human C1-esterase inhibitorComplement C1s subcomponenttarget
DB06404Human C1-esterase inhibitorPlasma kallikreintarget
DB06404Human C1-esterase inhibitorCoagulation factor XIItarget
DB06404Human C1-esterase inhibitorProthrombintarget
DB06404Human C1-esterase inhibitorCoagulation factor XItarget
DB06404Human C1-esterase inhibitorTissue-type plasminogen activatortarget
DB06474SibrotuzumabSeprasetarget
DB06550BivatuzumabCD44 antigentarget
DB06599LexatumumabTumor necrosis factor receptor superfamily member 10Btarget
DB06602ReslizumabInterleukin-5target
DB06607CatumaxomabEpithelial cell adhesion moleculetarget
DB06607CatumaxomabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB06607CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB06607CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB06607CatumaxomabT-cell surface glycoprotein CD3 epsilon chaintarget
DB06607CatumaxomabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB06612MepolizumabInterleukin-5target
DB06643DenosumabTumor necrosis factor ligand superfamily member 11target
DB06650OfatumumabB-lymphocyte antigen CD20target
DB06674GolimumabTumor necrosis factortarget
DB06681BelataceptT-lymphocyte activation antigen CD86target
DB06681BelataceptT-lymphocyte activation antigen CD80target
DB08870Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
DB08870Brentuximab vedotinCytochrome P450 3A4enzyme
DB08870Brentuximab vedotinATP-binding cassette sub-family B member 5transporter
DB08879BelimumabTumor necrosis factor ligand superfamily member 13Btarget
DB08902RaxibacumabProtective antigentarget
DB08935ObinutuzumabB-lymphocyte antigen CD20target
DB09029SecukinumabInterleukin-17Atarget
DB09033VedolizumabIntegrin alpha-4target
DB09033VedolizumabIntegrin beta-7target
DB09035NivolumabProgrammed cell death protein 1target
DB09036SiltuximabInterleukin-6target
DB09036SiltuximabCytochrome P450 3A4enzyme
DB09037PembrolizumabProgrammed cell death protein 1target
DB09045DulaglutideGlucagon-like peptide 1 receptortarget
DB09052BlinatumomabB-lymphocyte antigen CD19target
DB09052BlinatumomabT-cell surface glycoprotein CD3 delta chaintarget
DB09077DinutuximabGanglioside GD2target
DB09105Asfotase alfaSphingosine 1-phosphate receptor 1target
DB09105Asfotase alfaPyrophosphatetarget
DB09109Turoctocog alfaCoagulation factor IXtarget
DB09109Turoctocog alfaCoagulation factor Xtarget
DB09109Turoctocog alfaProthrombintarget
DB09302AlirocumabProprotein convertase subtilisin/kexin type 9target
DB09303EvolocumabProprotein convertase subtilisin/kexin type 9enzyme
DB09331DaratumumabADP-ribosyl cyclase 1target
DB09559NecitumumabEpidermal growth factor receptortarget
DB11300ThrombinProteinase-activated receptor 1target
DB11300ThrombinProteinase-activated receptor 4target
DB11300ThrombinCoagulation factor XItarget
DB11300ThrombinCoagulation factor XIII A chaintarget
DB11300ThrombinCoagulation factor XIII B chaintarget
DB11300ThrombinFibrinogen alpha chaintarget
DB11300ThrombinFibrinogen beta chaintarget
DB11300ThrombinFibrinogen gamma chaintarget
DB11300ThrombinCoagulation factor Vtarget
DB11300ThrombinCoagulation factor VIIItarget
DB11311ProthrombinFibrinogen alpha chaintarget
DB11311ProthrombinFibrinogen beta chaintarget
DB11311ProthrombinCoagulation factor XIII A chaintarget
DB11311ProthrombinCarboxypeptidase B2target
DB11311ProthrombinCoagulation factor Xenzyme
DB11569IxekizumabInterleukin-17Atarget
DB11595AtezolizumabProgrammed cell death 1 ligand 1target
DB11598Antithrombin III humanAntithrombin-IIItarget
DB11714DurvalumabProgrammed cell death 1 ligand 1target
DB11714DurvalumabT-lymphocyte activation antigen CD80target
DB11767SarilumabAlanine aminotransferase 1enzyme
DB11767SarilumabAlanine aminotransferase 2enzyme
DB11767SarilumabAspartate aminotransferaseenzyme
DB11767SarilumabCytochrome P450 3A4enzyme
DB11767SarilumabInterleukin-6 receptor subunit alphatarget
DB11767SarilumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB11834GuselkumabInterleukin-23 subunit alphatarget
DB11866RomosozumabSclerostintarget
DB11945AvelumabProgrammed cell death 1 ligand 1target
DB11988OcrelizumabB-lymphocyte antigen CD20target
DB12089Lorvotuzumab mertansineCytochrome P450 3A4enzyme
DB12119GevokizumabInterleukin-1 betatarget
DB12159DupilumabInterleukin-4 receptor subunit alphatarget
DB12240Polatuzumab vedotinCytochrome P450 3A4enzyme
DB12240Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintransporter
DB12240Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintarget
DB12250CixutumumabInsulin-like growth factor 1 receptortarget
DB12489Mirvetuximab SoravtansineCytochrome P450 3A4enzyme
DB12589DacetuzumabTumor necrosis factor receptor superfamily member 5target
DB12698IbalizumabT-cell surface glycoprotein CD4target
DB12698IbalizumabC-C chemokine receptor type 5target
DB12698IbalizumabC-X-C chemokine receptor type 4target
DB12845AmatuximabMesothelintarget
DB13133Von Willebrand Factor HumanCoagulation factor VIIItarget
DB13133Von Willebrand Factor HumanCollagen alpha-1(I) chaintarget
DB13133Von Willebrand Factor HumanA disintegrin and metalloproteinase with thrombospondin motifs 13enzyme
DB13149Protein S humanCoagulation factor Vtarget
DB13149Protein S humanCoagulation factor Xtarget
DB13149Protein S humanVitamin K-dependent protein Ctarget
DB13150Coagulation factor VII humanTissue factortarget
DB13150Coagulation factor VII humanCoagulation factor Xtarget
DB13150Coagulation factor VII humanCoagulation factor IXtarget
DB13192Antihemophilic factor humanCoagulation factor IXtarget
DB13192Antihemophilic factor humanCoagulation factor Xtarget
DB13192Antihemophilic factor humanVitamin K-dependent protein Cenzyme
DB13923EmicizumabCoagulation factor IXtarget
DB13923EmicizumabCoagulation factor Xtarget
DB13933Nonacog beta pegolCoagulation factor VIItarget
DB13933Nonacog beta pegolCoagulation factor VIIItarget
DB13933Nonacog beta pegolCoagulation factor Xtarget
DB13979BesilesomabCarcinoembryonic antigentarget
DB13999Moroctocog alfaCoagulation factor Xtarget
DB13999Moroctocog alfaPhytanoyl-CoA dioxygenase, peroxisomaltarget
DB13999Moroctocog alfaCoagulation factor IXtarget
DB13999Moroctocog alfaAsialoglycoprotein receptor 2target
DB13999Moroctocog alfa78 kDa glucose-regulated proteintarget
DB13999Moroctocog alfaCalreticulintarget
DB13999Moroctocog alfaCalnexintarget
DB13999Moroctocog alfaProtein ERGIC-53target
DB13999Moroctocog alfaProlow-density lipoprotein receptor-related protein 1target
DB13999Moroctocog alfaMultiple coagulation factor deficiency protein 2target
DB13999Moroctocog alfavon Willebrand factortarget
DB13999Moroctocog alfaProthrombinenzyme
DB13999Moroctocog alfaVitamin K-dependent protein Cenzyme
DB14004TildrakizumabInterleukin-23target
DB14004TildrakizumabCytochrome P450 4A11enzyme
DB14039ErenumabCalcitonin gene-related peptide type 1 receptortarget
DB14041FremanezumabCalcitonin gene-related peptide 1target
DB14041FremanezumabCalcitonin gene-related peptide 2target
DB14562Andexanet alfaTissue factor pathway inhibitortarget
DB12498MogamulizumabC-X-C chemokine receptor type 4target
DB14597LanadelumabPlasma kallikreintarget
DB09329Antihemophilic Factor (Recombinant), PEGylatedvon Willebrand factortarget
DB09329Antihemophilic Factor (Recombinant), PEGylatedvon Willebrand factorcarrier
DB11914LebrikizumabInterleukin-13target
DB11914LebrikizumabIL13 proteintarget
DB12023BenralizumabInterleukin-5 receptor subunit alphatarget
DB12023BenralizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB12202ZalutumumabEpidermal growth factor receptortarget
DB12520PlozalizumabC-C chemokine receptor type 2target
DB12773SifalimumabInterferon alpha-2target
DB14738Turoctocog alfa pegolVitamin K-dependent protein Cenzyme
DB14738Turoctocog alfa pegolCoagulation factor Xenzyme
DB14738Turoctocog alfa pegolCoagulation factor IXtarget
DB14738Turoctocog alfa pegolCoagulation factor Xtarget
DB14738Turoctocog alfa pegolProthrombintarget
DB14738Turoctocog alfa pegolvon Willebrand factorcarrier
DB05304GirentuximabCarbonic anhydrase 9target
DB05304GirentuximabInterleukin-2target
DB14762RisankizumabInterleukin-23target
DB00092AlefaceptT-cell surface antigen CD2target
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00092AlefaceptComplement C1r subcomponenttarget
DB00092AlefaceptComplement C1q subcomponent subunit Atarget
DB00092AlefaceptComplement C1q subcomponent subunit Btarget
DB00092AlefaceptComplement C1q subcomponent subunit Ctarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00092AlefaceptHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB05916CT-011Programmed cell death protein 1target
DB11572Thrombin alfaCoagulation factor XItarget
DB11572Thrombin alfaCoagulation factor VIIItarget
DB11572Thrombin alfaCoagulation factor Vtarget
DB11572Thrombin alfaCoagulation factor XIII A chaintarget
DB11572Thrombin alfaCoagulation factor XIII B chaintarget
DB11572Thrombin alfaFibrinogen alpha chaintarget
DB11572Thrombin alfaFibrinogen beta chaintarget
DB11572Thrombin alfaFibrinogen gamma chaintarget
DB11580RavulizumabComplement C5target
DB11731Depatuxizumab mafodotinEpidermal growth factor receptortarget
DB11731Depatuxizumab mafodotinTubulin beta chaintarget
DB12077UrelumabTumor necrosis factor receptor superfamily member 9target
DB13140BezlotoxumabClostridium difficile Toxin Btarget
DB13151Anti-inhibitor coagulant complexCoagulation factor Xtarget
DB13151Anti-inhibitor coagulant complexProthrombintarget
DB13151Anti-inhibitor coagulant complexFibrinogen alpha chaintarget
DB13151Anti-inhibitor coagulant complexFibrinogen beta chaintarget
DB13151Anti-inhibitor coagulant complexCoagulation factor XIII A chaintarget
DB13151Anti-inhibitor coagulant complexCoagulation factor Vtarget
DB13151Anti-inhibitor coagulant complexCoagulation factor VIIItarget
DB13151Anti-inhibitor coagulant complexCoagulation factor VIItarget
DB13151Anti-inhibitor coagulant complexProthrombinenzyme
DB13151Anti-inhibitor coagulant complexCoagulation factor VIIenzyme
DB13151Anti-inhibitor coagulant complexCoagulation factor VIIIenzyme
DB13151Anti-inhibitor coagulant complexCoagulation factor IXenzyme
DB13151Anti-inhibitor coagulant complexCoagulation factor Venzyme
DB13884Albutrepenonacog alfaCoagulation factor Xtarget
DB13884Albutrepenonacog alfaCoagulation factor VIIIenzyme
DB14012BurosumabFibroblast growth factor 23target
DB14040EptinezumabCalcitonin gene-related peptide 1target
DB14040EptinezumabCalcitonin gene-related peptide 2target
DB14042GalcanezumabCalcitonin gene-related peptide 1target
DB14042GalcanezumabCalcitonin gene-related peptide 2target
DB14707CemiplimabProgrammed cell death protein 1target
DB14864BrolucizumabVascular endothelial growth factor Atarget